Table 1 Age, KPS, CR/PR, PFS, and prior chemotherapy regimen demographics of studiesa
Trial No. | Drugs | N | PR/CR | PFS6 | PFS9 | PFS12 | Age (SD) | KPS (SD) | No. Prior Chemo (SD) |
|---|---|---|---|---|---|---|---|---|---|
1 | Gleevec, phase I/II [39] | 22 | 0% | 7.7% | 4.8% | 3.4% | 46.8 (11.5) | 83.2 (10.9) | 1.3 (0.5) |
2 | DM86-15: IV carboplatin [38] | 11 | 9% | 24.9% | 18.6% | 6.5% | 36.3 (8.6) | 82.7 (10.1) | 1.0 (0.0) |
3 | Miscellaneous agentsb [45] | 32 | 0% | 14.2% | 9.8% | 9.3% | 40.5 (12.4) | 84.2 (14.2) | 2.7 (0.6) |
4 | Carboplatin with VP16 [42, 45] | 19 | 5% | 11.9% | 10.4% | 9.5% | 41.3 (8.9) | 85.4 (13.9) | 3.0 (0.8) |
5 | CPT-11 alone or with thalidomide, CDDP, or tamoxifen [45] | 22 | 9% | 21.0% | 15.0% | 15.0% | 41.3 (10.2) | 80.0 (13.6) | 3.0 (0.9) |
6 | DM92-109: interferon-beta arm [38, 41] | 28 | 17% | 20.5% | 18.4% | 16.7% | 42.7 (9.4) | 85.4 (8.8) | 1.5 (1.0) |
7 | DM88-130: DFMO [37] | 42 | 14% | 29.1% | 21.1% | 19.1% | 38.0 (11.2) | 84.3 (11.7) | 1.8 (1.2) |
8 | Temozolomide [40] | 126 | 33% | 46.0% | 25.0% | 19.6% | 42.6 (11.2) | 83.9 (10.8) | 1.1 (0.8) |
9 | Temozolomide with cRA [45] | 37 | 11% | 38.6% | 23.8% | 20.8% | 41.0 (11.4) | 84.3 (14.8) | 2.4 (0.7) |
10 | DM92-109: interferon-beta with cRA arm [38, 41] | 30 | 7% | 42.0% | 28.9% | 22.0% | 42.5 (8.3) | 84.6 (8.1) | 1.5 (0.9) |
11 | Temozolomide [45] | 56 | 4% | 33.2% | 29.3% | 23.3% | 39.4 (9.5) | 84.6 (11.4) | 2.5 (0.6) |
12 | cRA [45] | 27 | 11% | 29.2% | 25.9% | 25.9% | 42.2 (12.8) | 83.0 (13.0) | 2.6 (0.8) |
13 | BCNU or CCNU alone or with 6-TG [45] | 31 | 13% | 36.4% | 36.4% | 27.5% | 44.1 (14.4) | 83.5 (11.9) | 2.3 (0.5) |
14 | Carboplatin with cRA [45] | 15 | 0% | 44.4% | 36.8% | 31.5% | 39.1 (9.5) | 82.9 (13.8) | 2.7 (0.8) |
15 | Temozolomide with marimastat [44] | 18 | 7% | 40.0% | 38.2% | 36.4% | 38.6 (9.9) | 88.2 (13.3) | 2.2 (0.4) |
16 | DM89-092: carboplatin with 5-FU & procarbazine [38, 43] | 13 | 17% | 47.1% | 43.9% | 41.1% | 43.5 (16.9.9) | 81.7 (11.9) | 0.9 (1.0) |